Experienced in Hypopituitarism

Matthias Hepprich

Basel, BS, CH 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Hypopituitarism
Basel, BS, CH 
OverviewLocationsClinical Research

Overview

Matthias Hepprich practices in Basel, Switzerland. Mr. Hepprich is rated as an Experienced expert by MediFind in the treatment of Hypopituitarism. His top areas of expertise are Low Blood Sugar, Insulinoma, Ectopic Cushing's syndrome, Gastric Bypass, and Hormone Replacement Therapy (HRT).

His clinical research consists of co-authoring 22 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Hypopituitarism.

Gender
Male

Locations

Basel, BS, Switzerland
Other Locations
Olten, SO, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Canakinumab for the Treatment of Postprandial Hypoglycemia - CanpHy Study
Canakinumab for the Treatment of Postprandial Hypoglycemia - CanpHy Study
Enrollment Status: Recruiting
Publish Date: January 29, 2025
Intervention Type: Drug
Study Phase: Phase 3
Empagliflozin for the Treatment of Postprandial Hypoglycemia
Empagliflozin for the Treatment of Postprandial Hypoglycemia
Enrollment Status: Terminated
Publish Date: August 16, 2024
Intervention Type: Drug, Other
Study Drug: Empagliflozin
Study Phase: Phase 3
Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia
Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia
Enrollment Status: Completed
Publish Date: May 08, 2024
Intervention Type: Drug
Study Phase: Not Applicable
Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes: a Randomized, Placebo-controlled Study
Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes: a Randomized, Placebo-controlled Study
Enrollment Status: Active_not_recruiting
Publish Date: February 20, 2024
Intervention Type: Drug, Other
Study Drugs: Empagliflozin, Anakinra
Study Phase: Phase 2
Canakinumab in Patients With COVID-19 and Type 2 Diabetes - CanCovDia Trial
Canakinumab in Patients With COVID-19 and Type 2 Diabetes - CanCovDia Trial
Enrollment Status: Completed
Publish Date: September 08, 2021
Intervention Type: Drug
Study Drug: Canakinumab
Study Phase: Phase 3
View 4 Less Clinical Trials

22 Total Publications

Canakinumab for the treatment of postprandial hypoglycaemia: study protocol for a randomised, placebo-controlled, parallel-group, double-blind, multicentric, superiority trial-the CanpHy study.
Canakinumab for the treatment of postprandial hypoglycaemia: study protocol for a randomised, placebo-controlled, parallel-group, double-blind, multicentric, superiority trial-the CanpHy study.
Journal: BMJ open
Published: May 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hepprich's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile